Artigos

Search for articles

BJO Oncology - Placeholder

Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report

ABSTRACT Metastatic castration-resistant prostate cancer (mCRPC) is an extremely severe disease that relentlessly evolves to death. Over the past few years, we have seen significant improvements in the different types of treatments available, which have positively impacted several clinical outcomes, including higher survival rates and better quality of life. Since...